These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 22829196)
1. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Kleber M; Ihorst G; Terhorst M; Koch B; Deschler B; Wäsch R; Engelhardt M Blood Cancer J; 2011 Sep; 1(9):e35. PubMed ID: 22829196 [TBL] [Abstract][Full Text] [Related]
2. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851 [TBL] [Abstract][Full Text] [Related]
3. Comparative Evaluation of Common Comorbidity Scores and Freiburger Comorbidity Index as Prognostic Variables in a Real Life Multiple Myeloma Population. Onec B; Okutan H; Albayrak M; Can ES; Aslan V; Soyer Kosemehmetoglu O; Unver Koluman B Indian J Hematol Blood Transfus; 2016 Dec; 32(4):424-430. PubMed ID: 27812251 [TBL] [Abstract][Full Text] [Related]
4. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Kleber M; Ihorst G; Gross B; Koch B; Reinhardt H; Wäsch R; Engelhardt M Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):541-51. PubMed ID: 23810244 [TBL] [Abstract][Full Text] [Related]
5. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Kleber M; Ihorst G; Deschler B; Jakob C; Liebisch P; Koch B; Sezer O; Engelhardt M Eur J Haematol; 2009 Dec; 83(6):519-27. PubMed ID: 19614956 [TBL] [Abstract][Full Text] [Related]
6. A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia. Terwey TH; Hemmati PG; Martus P; Dietz E; Vuong LG; Massenkeil G; Dörken B; Arnold R Haematologica; 2010 May; 95(5):810-8. PubMed ID: 20007143 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the Freiburg and Charlson comorbidity indices in predicting overall survival in elderly patients with newly diagnosed multiple myeloma. Kim SM; Kim MJ; Jung HA; Kim K; Kim SJ; Jang JH; Kim WS; Jung CW Biomed Res Int; 2014; 2014():437852. PubMed ID: 25114902 [TBL] [Abstract][Full Text] [Related]
8. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Engelhardt M; Dold SM; Ihorst G; Zober A; Möller M; Reinhardt H; Hieke S; Schumacher M; Wäsch R Haematologica; 2016 Sep; 101(9):1110-9. PubMed ID: 27479825 [TBL] [Abstract][Full Text] [Related]
9. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Engelhardt M; Domm AS; Dold SM; Ihorst G; Reinhardt H; Zober A; Hieke S; Baayen C; Müller SJ; Einsele H; Sonneveld P; Landgren O; Schumacher M; Wäsch R Haematologica; 2017 May; 102(5):910-921. PubMed ID: 28154088 [TBL] [Abstract][Full Text] [Related]
10. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465 [TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes in Elderly Patients Treated for Oral Cavity Squamous Cell Carcinoma. Chen JJ; Shah JL; Harris JP; Bui TT; Schaberg K; Kong CS; Kaplan MJ; Divi V; Schoppy D; Le QT; Hara WY Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):775-783. PubMed ID: 28602409 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation. Obiozor C; Subramaniam DP; Divine C; Shune L; Singh AK; Lin TL; Abhyankar S; Chen GJ; McGuirk J; Ganguly S Biol Blood Marrow Transplant; 2017 Oct; 23(10):1641-1645. PubMed ID: 28603071 [TBL] [Abstract][Full Text] [Related]
13. Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for Lung Cancer. Singh N; Singh PS; Aggarwal AN; Behera D Clin Lung Cancer; 2016 May; 17(3):205-213.e1. PubMed ID: 26589440 [TBL] [Abstract][Full Text] [Related]
14. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Firat S; Bousamra M; Gore E; Byhardt RW Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):1047-57. PubMed ID: 11958901 [TBL] [Abstract][Full Text] [Related]
15. Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography. Marani C; Raiola AM; Morbelli S; Dominietto A; Ferrarazzo G; Avenoso D; Giannoni L; Varaldo R; Gualandi F; Grazia D; Lamparelli T; Bregante S; Van Lint MT; Ibatici A; Bovis F; Lemoli RM; Gobbi M; Bacigalupo A; Angelucci E Biol Blood Marrow Transplant; 2018 Dec; 24(12):2501-2508. PubMed ID: 30041010 [TBL] [Abstract][Full Text] [Related]
16. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Sorror M; Storer B; Sandmaier BM; Maloney DG; Chauncey TR; Langston A; Maziarz RT; Pulsipher M; McSweeney PA; Storb R Cancer; 2008 May; 112(9):1992-2001. PubMed ID: 18311781 [TBL] [Abstract][Full Text] [Related]
17. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Firat S; Byhardt RW; Gore E Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):357-64. PubMed ID: 12243808 [TBL] [Abstract][Full Text] [Related]
18. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia. Khalil MMI; Lipton JH; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Messner HA; Michelis FV Eur J Haematol; 2018 Feb; 100(2):198-205. PubMed ID: 29168234 [TBL] [Abstract][Full Text] [Related]
19. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Sperr WR; Wimazal F; Kundi M; Baumgartner C; Nösslinger T; Makrai A; Stauder R; Krieger O; Pfeilstöcker M; Valent P Ann Oncol; 2010 Jan; 21(1):114-9. PubMed ID: 19605505 [TBL] [Abstract][Full Text] [Related]
20. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC. Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]